scholarly journals Subretinal alteplase injections in massive subretinal hemorrhage due to age‑related macular degeneration: A case report series

2020 ◽  
Vol 20 (6) ◽  
pp. 1-1
Author(s):  
Radu Ochinciuc ◽  
Florian Balta ◽  
Daniel Branisteanu ◽  
Marian Burcea ◽  
Mihail Zemba ◽  
...  
Keyword(s):  
Case Report ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Subretinal Hemorrhage ◽  
Age Related

AGE-RELATED MACULAR DEGENERATION WITH MASSIVE SUBRETINAL HEMORRHAGE EASILY REMOVED THROUGH A RETINAL BREAK

2008 ◽  
Vol 2 (4) ◽  
pp. 292-295
Author(s):  
Takayuki Baba ◽  
Mariko Kubota-Taniai ◽  
Yoshinori Mitamura ◽  
Shuichi Yamamoto
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Subretinal Hemorrhage ◽  
Retinal Break ◽  
Age Related

scholarly journals Intravitreal bevacizumab combined with infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: case report series

2013 ◽  
Vol 76 (3) ◽  
pp. 180-184 ◽  
Author(s):  
Luiz Guilherme Azevedo de Freitas ◽  
David Leonardo Cruvinel Isaac ◽  
William Thomas Tannure ◽  
Luís Alexandre Rassi Gabriel ◽  
Ricardo Gomes dos Reis ◽  
...  
Keyword(s):  
Case Report ◽  
Macular Degeneration ◽  
Choroidal Neovascularization ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials

Ophthalmology ◽  
2016 ◽  
Vol 123 (2) ◽  
pp. 352-360 ◽  
Author(s):  
Gui-shuang Ying ◽  
Maureen G. Maguire ◽  
Ebenezer Daniel ◽  
Juan E. Grunwald ◽  
Osama Ahmed ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Subretinal Hemorrhage ◽  
Age Related ◽  
Anticoagulant Drugs

Magnification, yellow filter and prisms low-vision aid in age-related macular degeneration: A case report

2021 ◽  
Author(s):  
J.-M. Sánchez-González ◽  
C. Rocha-de-Lossada ◽  
R. Rachwani-Anil ◽  
I. Castellanos-Gómez ◽  
F. Alonso-Aliste
Keyword(s):  
Case Report ◽  
Macular Degeneration ◽  
Low Vision ◽  
Age Related Macular Degeneration ◽  
Yellow Filter ◽  
Age Related

scholarly journals Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography – case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Martin Pencak ◽  
Miroslav Veith
Keyword(s):  
Optical Coherence Tomography ◽  
Case Report ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Optical Coherence ◽  
Intravitreal Ranibizumab ◽  
Asymmetric Response ◽  
Age Related

Abstract Background To present a case report of a patient with a mixed choroidal neovascular membrane (CNV) with an asymmetric response to ranibizumab diagnosed on optical coherence tomography angiography (OCTa). Case presentation A 61-year-old male was referred to our department in September 2017 due to decreased vision in his left eye. Best-corrected visual acuity (BCVA) was 43 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye. Macular edema was present in the left eye, and a mixed CNV was identified on the OCTa. Therapy with intravitreal ranibizumab was commenced. After 5 ranibizumab injections, the BCVA was 42 ETDRS letters, and considerable intraretinal edema was still present. OCTa showed a resolution of the type 2 lesion of the mixed CNV; however, the type 1 lesion had continued to grow. The patient was then switched to intravitreal aflibercept. After 3 monthly aflibercept injections, the BCVA improved to 53 ETDRS letters, and a reduction of the edema was observed on the optical coherence tomography (OCT). OCTa showed a decrease in both the area and vessel density in the type 1 lesion of the CNV. Therapy with aflibercept was continued; however, while the intraretinal edema continued to improve, atrophy developed in the macula and the BCVA worsened to 43 ETDRS letters. Conclusions Ranibizumab nonresponse in a neovascular age-related macular degeneration is not uncommon. However, to our knowledge, this is the first described case of an asymmetric response to ranibizumab in a mixed CNV. While the type 2 lesion of the CNV reacted swiftly to the ranibizumab therapy, the type 1 lesion continued to grow. As with some other cases of ranibizumab resistance, switching to aflibercept proved effective.

Sign in / Sign up

Export Citation Format

Share Document